Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060147 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04060147 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 11 participants.
The verdict
NCT04060147, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
Interventions
- DRUG Cilofexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04060147
The ClinicalTrials.gov registry entry for NCT04060147 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cilofexor is the first listed.
NCT04060147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04060147 about?
NCT04060147 is a clinical study titled "Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis". The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
What is the current status of trial NCT04060147?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-10-17. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT04060147?
The interventions under investigation include: Cilofexor (DRUG).
Who is sponsoring clinical trial NCT04060147?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.